Gender dysphoria and headache

YALINAY DİKMEN P., ÇİMENTEPE SEZER Ç., KOÇOĞLU M., Kosak S., Tecirli N. D., ONUR AYSEVENER B. E.

19th International Headache Congress of International-Headache-Society, Dublin, İrlanda, 5 - 08 Eylül 2019, cilt.39, ss.85 identifier

  • Yayın Türü: Bildiri / Özet Bildiri
  • Cilt numarası: 39
  • Basıldığı Şehir: Dublin
  • Basıldığı Ülke: İrlanda
  • Sayfa Sayıları: ss.85
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet

Özet

Gender dysphoria and headache Pinar Yalinay Dikmen1,*, Cagrı Cimentepe2 , Mahmut Kocoglu2 , Seda Kosak1 , Nese Direk Tecirli2 and Behice Elif Onur Aysevener2 1

Neurology, Acibadem Mehmet Ali Aydınlar University, School of Medicine, Istanbul 2 Psychiatry, 9 Eylul University, Faculty of Medicine, Izmir, Turkey

Objective: Gender dysphoria is the distress a person experiences as a result of the sex and gender they were assigned at birth. The prevalence and demographics of gender dysphoria vary according to geographical location and has not been well-documented in Turkey. There are also significant research gaps in headache and migraine’s effect on transgender population. The aim of this study was to search for headache incidence and type in people with gender dysphoria (female-to-male) and association between headache and hormone replacement therapy (HRT). Methods: A total of 50 patients (24.3 3.8) who were diagnosed as gender dysphoria (female-to-male) and followed by Psychiatry Department of 9 Eylul University, Faculty of Medicine, Turkey were recruited in the study. Participants were asked whether they were currently receiving hormone replacement therapy or not. All patients filled out Beck Depression Inventory (BDI) and Beck Anxiety Inventory (BAI). Headache was diagnosed using a questionnaire which consisting of 40 questions and assessed by a neurology specialist. Results: Forty percent of the participants (n ¼ 20) were currently receiving hormone replacement therapy, while 60% of the patients were not. The mean score of the BDI and BAI were respectively, [(8.27 7.37); (8,98 7,12)]. The patients were classified as a tension type headache (TTH) (n ¼ 14, 28%) and migraine (n ¼ 28, 56%). Patients with TTH and migraine were mostly infrequent episodic type respectively, [(n ¼ 13, 93%) (n ¼ 24, 82%)]. The most common triggers for headache reported by the patients were stress and sleep disturbances. Twenty-two participants with migraine were currently receiving hormone replacement therapy (61%) and 68.2 percent of them (n ¼ 15) reported that their headache frequency did not change after starting hormone replacement therapy